《大行報告》中金上調名創優品(MNSO.US)目標價至22.73美元 評級「跑贏行業」
中金發表報告指,名創優品(MNSO.US)預告第三財季non-IFRS淨利潤不低於4億元人民幣,按年增長逾260%,按季增長亦逾7%。考慮終端零售環境持續好轉,中金分別上調對公司今明兩個財年每股盈利預測13%及8%至5.06及6.52元人民幣,相應上調目標價8%至22.73美元。
中金預計,3月銷售額繼續延續良好增長趨勢。同時疫情後加盟商開店積極性提高,預計首季度開店數量實現較好增長,門店增長和單店恢復共同帶動名創優品內地業務收入按年增長約20至25%,預計季內收入按年增長20%。
該行預計,3月海外GMV繼續保持良好勢頭,季內海外GMV增長約40%。考慮快速的GMV增長及經營提效,預計海外直營業務在第三財季仍有正向盈利貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.